Alterations in cardiac muscarinic acetylcholine receptors in mice with autoimmune myocarditis and association with circulating muscarinic receptor-related autoantibodies

Leirós, Claudia Pérez; Goren, Nora; Sterin‐Borda, Leonor; Lustig, Livia; Borda, Enri

doi:10.1007/bf01827430

Cited by 16 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,46,47 Auto-antibodies against contractile structures, 48–50 proteins involved in energy metabolism/transfer, 51,52 ion channels and transporters, 53 and sarcolemmal receptors 54 have been identified in myocarditis. Circulating cardiac auto-antibodies, in particular antibodies against cardiac myosin heavy chain, may play a key role as a clinical and pathogenetic marker and may also have some prognostic value.…”

Section: Diagnosismentioning

confidence: 99%

Acute viral myocarditis

Dennert

Crijns

Heymans

2008

European Heart Journal

348

299

View full text Add to dashboard Cite

Acute myocarditis is one of the most challenging diagnosis in cardiology. At present, no diagnostic gold standard is generally accepted, due to the insensitivity of traditional diagnostic tests. This leads to the need for new diagnostic approaches, which resulted in the emergence of new molecular tests and a more detailed immunohistochemical analysis of endomyocardial biopsies. Recent findings using these new diagnostic tests resulted in increased interest in inflammatory cardiomyopathies and a better understanding of its pathophysiology, the recognition in overlap of virus-mediated damage, inflammation, and autoimmune dysregulation. Novel results also pointed towards a broader spectrum of viral genomes responsible for acute myocarditis, indicating a shift of enterovirus and adenovirus to parvovirus B19 and human herpes virus 6. The present review proposes a general diagnostic approach, focuses on the viral aetiology and associated autoimmune processes, and reviews treatment options for patients with acute viral myocarditis.

show abstract

Section: Diagnosismentioning

confidence: 99%

Acute viral myocarditis

Dennert

Crijns

Heymans

2008

European Heart Journal

348

299

View full text Add to dashboard Cite

show abstract

“…3 In fact, in cases of myocarditis and dilated cardiomyopathy there can be anti-heart autoantibodies against various tissues, including contractile structure (myosin), extracellular matrix (laminin), proteins involved in energy metabolism and conduction, ion channel/transporter, and sarcomere receptor. [133][134][135][136][137][138][139] Anti-heart autoantibodies are observed in up to 60% of all patients with myocarditis in the chronic phase. 21 Conversely, the corresponding percentage is ≈1% in those with heart disease without myocarditis and ≈3% in healthy persons.…”

Section: ▋ 341 Anti-heart Autoantibodiesmentioning

confidence: 99%

JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis

Nagai

Inomata

Kohno

et al. 2023

Circ J

View full text Add to dashboard Cite

In 2009, the "Guidelines for diagnosis and treatment of myocarditis (JCS 2009)" were issued by the Japanese Circulation Society (JCS). 1 Although this guideline has been widely used in clinical practice for more than a decade, it is certain that they now require adjustment in line with recent trends.Recent Position Statements and Expert Consensuses published in Europe 3 and the USA 2 have shown a shift to general classification of myocarditis into acute myocarditis and chronic inflammatory cardiomyopathy, resulting in a decrease in the use of the term "chronic myocarditis" worldwide. This is attributable to the fact that the understanding of the etiology, pathological condition, and clinical course of myocarditis has gradually deepened through AKIN Acute Kidney Injury Network APACHE Acute Physiology and Chronic Health Evaluation AST aspartate aminotransferase BNP B-type natriuretic peptide BTT bridge to transplantation BiVAD biventricular assist device CK creatine kinase CK-MB creatine kinase myocardial bound COVID-19 COronaVirus Infectious Disease, emerged in 2019 CRP C-reactive protein CRT-D cardiac resynchronization therapy defibrillator CTLA-4 cytotoxic T lymphocyte-associated protein 4 CQs Clinical Questions DI disagreement index DIC disseminated intravascular coagulation DLST drug-induced lymphocyte stimulation test 1. Process of Preparation ▋ 1.1 Purpose, Users, and Targeted Patients of the Guidelines ▋ 1.1.1 Purpose To provide practice guidelines for appropriate diagnosis and treatment management to physicians engaged in clinical care of patients with myocarditis. ▋ 1.1.2 Expected Users The present Guidelines were prepared in the expectation that cardiologists, cardiovascular surgeons, pediatricians, intensive care physicians, general internists, general practitioners, nurses, and other medical personnel who are engaged in the clinical care of myocarditis patients would use them when devising treatment strategies. It is alsoStep 4: Evaluation and Finalization of the Clinical Practice Guidelines The content of the Guidelines was reviewed by external reviewers and based their reports, modifications were made as necessary. ▋ 1.5 PublicationThe final draft was published after approval of the JCS Clinical Practice Guidelines Committee. ▋ 1.6 Conflict of Interest (COI)Conflict of interest, if any, was declared according to the rules prescribed by the JCS. The declaration covered 3 years from 2020 to 2022.

show abstract

Cruzipain induces autoantibodies against cardiac muscarinic acetylcholine receptors. Functional and pathological implications

Sterin‐Borda¹,

Giordanengo²,

Joensen³

et al. 2003

Eur J Immunol

View full text Add to dashboard Cite

The goal of this study was to investigate whether cruzipain, a Trypanosoma cruzi immunodominant antigen, was able to induce antibodies reactive to the cardiac M 2 muscarinic acetylcholine receptor (M 2 mAChR). Immunization with cruzipain that was devoid of enzyme activity triggered IgG antibodies against cardiac M 2 mAChR. By radioligand competition assay we proved that the anti-cruzipain IgG fraction, purified from serum, inhibited binding of the specific M 2 mAChR radioligand [ 3 H]quinuclidinyl benzilate. We also demonstrated that anti-cruzipain IgG reacted against the second extracellular loop of the M 2 mAChR. The corresponding affinity-purified serum anti-M 2 e2 IgG (reacting against a synthetic peptide corresponding to this loop in humans) displayed agonist-like activity associated with specific M 2 mAChR activation -increase of cGMP, inositol phosphate accumulation and nitric oxide synthase activity -triggering a decrease in myocardial contractility. Moreover, the same IgG fraction decreased heart frequency, related to inhibition of adenylate cyclase activity. These results imply that cruzipain plays a role in the production of antibodies against M 2 mAChR, which have been related to the pathogenesis of dysautonomic syndrome described in Chagas' disease.

show abstract

Alterations in cardiac muscarinic acetylcholine receptors in mice with autoimmune myocarditis and association with circulating muscarinic receptor-related autoantibodies

Cited by 16 publications

References 35 publications

Acute viral myocarditis

Acute viral myocarditis

JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis

Cruzipain induces autoantibodies against cardiac muscarinic acetylcholine receptors. Functional and pathological implications

Contact Info

Product

Resources

About